ClearCut Medical Ltd. is an Israeli medical device company that developed the ClearCoast™ system, a novel portable MRI scanner for intra-operative margin assessment during Breast Conserving Surgery (BCS) as the first application. The ClearCoast™ system is CE marked and the company is working towards an FDA marketing approval.
Hezi Himelfarb
hezi@clrcut.com
5 David Fikes St., Rehovot 7632805, Israel
0522497044
https://www.clrcut.com/
Company's Solutions
ClearCut developed a novel, proprietary MRI portable scanner, the ClearCoast™ system, which was designed for use in the operating room during cancer surgery with breast conserving surgery as the first application.
The excised tissue is placed inside the ClearCoast™ Tissue Container and is loaded into the ClearCoast™ system for a quick MRI scan using Diffusion Weighted MRI (DW-MRI) protocols.
Malignant tissues have lower Apparent Diffusion Coefficient (ADC) and are shown in red on the system’s screen, while normal tissues have higher ADC and are shown in blue, making it simple for the user to assess the tissue margin status.
The surgeon can see the results in real-time, while the patient is still in the operating room and based on an easy-to-understand image, take a quick decision, whether to excise more tissue or not.
This real-time “on-the-spot” margin assessment can significantly reduce the need for a 2nd operation and thus reduces patient distress. In addition, for the medical center, it increases efficiency, strengthens facility reputation, and reduces costs.
Prominent Case Study
While the CleaCoast provides real-time margin assessment in breast conserving surgery, the entire surgery workflow remains the same and is not affected in anyway.